MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.4380 +0.1007 (+29.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Revenue Jumps 85 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Femasys Announces Second Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women-- 
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Femasys In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up ↗
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday. 
Via Stocktwits
News headline image
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Femasys Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Femasys's Future ↗
 
Via Benzinga
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic ↗
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million. 
Via Stocktwits
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option 
From Femasys Inc.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Assessing Femasys: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story